Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03011684
PHASE3

Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.

Key Details

Gender

FEMALE

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

309

Start Date

2016-07-21

Completion Date

2026-03-31

Last Updated

2025-05-08

Healthy Volunteers

No

Conditions

Interventions

DRUG

Tamoxifen

Given orally

DRUG

Letrozole

Given orally

Locations (1)

University of California at San Francisco

San Francisco, California, United States